Cargando…

Randomized, double-blind, crossover study comparing DFN-11 injection (3 mg subcutaneous sumatriptan) with 6 mg subcutaneous sumatriptan for the treatment of rapidly-escalating attacks of episodic migraine

BACKGROUND: A 6-mg dose of SC sumatriptan is the most efficacious and fast-acting acute treatment for migraine, but a 3-mg dose of SC sumatriptan may improve tolerability while maintaining efficacy. METHODS: This randomized, double-blind, crossover study compared the efficacy and tolerability of 3 m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cady, Roger K., Munjal, Sagar, Cady, Ryan J., Manley, Heather R., Brand-Schieber, Elimor
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Milan 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5296269/ https://www.ncbi.nlm.nih.gov/pubmed/28176235 http://dx.doi.org/10.1186/s10194-016-0717-7

Ejemplares similares

Efficacy and safety of DFN-11 (sumatriptan injection, 3 mg) in adults with episodic migraine: an 8-week open-label extension study
por: Landy, Stephen, et al.
Publicado: (2018)

Efficacy and safety of DFN-11 (sumatriptan injection, 3 mg) in adults with episodic migraine: a multicenter, randomized, double-blind, placebo-controlled study
por: Landy, Stephen, et al.
Publicado: (2018)

A multicenter, open-label, long-term safety and tolerability study of DFN-02, an intranasal spray of sumatriptan 10 mg plus permeation enhancer DDM, for the acute treatment of episodic migraine
por: Munjal, Sagar, et al.
Publicado: (2017)

Human factors validation study of 3 mg sumatriptan autoinjector, for migraine patients
por: Brand-Schieber, Elimor, et al.
Publicado: (2016)

DFN-02, Sumatriptan 10 mg Nasal Spray with Permeation Enhancer, for the Acute Treatment of Migraine: A Randomized, Double-Blind, Placebo-Controlled Study Assessing Functional Disability and Subject Satisfaction with Treatment
por: Lipton, Richard B., et al.
Publicado: (2019)

Subcutaneous sumatriptan delivery devices: comparative ease of use and preference among migraineurs
por: Andre, Anthony D, et al.
Publicado: (2017)

Efficacy, Tolerability, and Safety of DFN‐15 (Celecoxib Oral Solution, 25 mg/mL) in the Acute Treatment of Episodic Migraine: A Randomized, Double‐Blind, Placebo‐Controlled Study
por: Lipton, Richard B., et al.
Publicado: (2019)

Subcutaneous delivery of sumatriptan in the treatment of migraine and primary headache
por: Moore, Johanna C, et al.
Publicado: (2012)

AVP-825 Breath-Powered Intranasal Delivery System Containing 22 mg Sumatriptan Powder vs 100 mg Oral Sumatriptan in the Acute Treatment of Migraines (The COMPASS Study): A Comparative Randomized Clinical Trial Across Multiple Attacks
por: Tepper, Stewart J, et al.
Publicado: (2015)

Sumatriptan (50 and 100 mg) in repeated migraine attacks: a patient preference study
por: Zanchin, Georgio, et al.
Publicado: (2000)

Treatment satisfaction and efficacy of the rapid release formulation of sumatriptan 100 mg tablets utilising an early intervention paradigm in patients previously unsatisfied with sumatriptan
por: Newman, L C, et al.
Publicado: (2008)

Sumatriptan 6 mg subcutaneous as an effective migraine treatment in patients with cutaneous allodynia who historically fail to respond to oral triptans
por: Diamond, S., et al.
Publicado: (2007)

Influence of sumatriptan on the autonomic system during migraine attacks
por: Dalla Volta, G., et al.
Publicado: (2006)

Comparison between Intravenous Sodium Valproate and Subcutaneous Sumatriptan for Treatment of Acute Migraine Attacks; Double-Blind Randomized Clinical Trial
por: Rahimdel, Abolghasem, et al.
Publicado: (2014)

The effect of weight, body mass index, age, sex, and race on plasma concentrations of subcutaneous sumatriptan: a pooled analysis
por: Munjal, Sagar, et al.
Publicado: (2016)

Treatment with sumatriptan 50 mg in the mild phase of migraine attacks in patients with infrequent attacks: a randomised, double-blind, placebo-controlled study
por: Tfelt-Hansen, P., et al.
Publicado: (2006)

Efficacy of Sumatriptan/Placebo versus Sumatriptan/Propofol Combination in Acute Migraine; a Randomized Clinical Trial
por: Farahmand Rad, Reza, et al.
Publicado: (2022)

Does repeated subcutaneous administration of sumatriptan produce an unfavorable evolution in cluster headache?
por: Dousset, Virginie, et al.
Publicado: (2004)

A comparison of preference for and efficacy of tablet formulations of sumatriptan (50 mg and 100 mg), naratriptan (2.5 mg), rizatriptan (10 mg), and zolmitriptan (2.5 mg) in the acute treatment of migraine
por: Dahlöf, Carl, et al.
Publicado: (2004)

Improved Pharmacokinetics of Sumatriptan With Breath Powered™ Nasal Delivery of Sumatriptan Powder
por: Obaidi, Mohammad, et al.
Publicado: (2013)

Harnessing Intranasal Delivery Systems of Sumatriptan for the Treatment of Migraine
por: Assadpour, Sara, et al.
Publicado: (2022)

Metabolism of sumatriptan revisited
por: Pöstges, Timo, et al.
Publicado: (2023)

Subcutaneous sumatriptan: results of a peculiar, unpublished, comparative, double-blind, randomised, and controlled trial
por: Tfelt-Hansen, Peer
Publicado: (2011)

The Use of Neuroimaging for Predicting Sumatriptan Treatment Response in Patients With Migraine
por: Wu, Jr-Wei, et al.
Publicado: (2022)

Pharmacokinetics of DFN-15, a Novel Oral Solution of Celecoxib, Versus Celecoxib 400-mg Capsules: A Randomized Crossover Study in Fasting Healthy Volunteers
por: Pal, Arindam, et al.
Publicado: (2017)

Pharmacokinetics study of chitosan-coated liposomes containing sumatriptan in the treatment of migraine
por: Assadpour, Sara, et al.
Publicado: (2022)

Efficacy and safety of DFN-15, an oral liquid formulation of celecoxib, in adults with migraine: a multicenter, randomized, placebo-controlled, double-blind, crossover study
por: Munjal, Sagar, et al.
Publicado: (2017)

Efficacy of oxygen inhalation in sumatriptan refractory “high altitude” cluster headache attacks
por: Mampreso, Edoardo, et al.
Publicado: (2009)

A Randomized, Double-Blind, Placebo-Controlled Study of Breath Powered Nasal Delivery of Sumatriptan Powder (AVP-825) in the Treatment of Acute Migraine (The TARGET Study)
por: Cady, Roger K, et al.
Publicado: (2015)

Pharmacokinetics of sumatriptan in non-respondent and in adverse drug reaction reporting migraine patients
por: Sternieri, E., et al.
Publicado: (2005)

Sumatriptan–naproxen fixed combination for acute treatment of migraine: a critical appraisal
por: Khoury, Chaouki K, et al.
Publicado: (2010)

Metoclopramide versus sumatriptan for treatment of migraine headache: A randomized clinical trial
por: Talabi, Saeid, et al.
Publicado: (2013)

Cilostazol induced migraine does not respond to sumatriptan in a double blind trial
por: Falkenberg, Katrine, et al.
Publicado: (2018)

Predicting Sumatriptan Responsiveness Based on Structural Connectivity in Patients Newly Diagnosed With Migraine
por: Lee, Dong Ah, et al.
Publicado: (2023)

Subcutaneous sumatriptan for the treatment of postcraniotomy pain (SUPS trial): protocol for a randomised double-blinded placebo controlled trial
por: Licina, Ana, et al.
Publicado: (2019)

Spontaneous splenic infarction associated with sumatriptan use
por: Arora, A., et al.
Publicado: (2006)

Bilateral Renal Infarctions During the Use of Sumatriptan
por: Abramovitz, Blaise, et al.
Publicado: (2018)

Functional Hybrid Nanoemulsions for Sumatriptan Intranasal Delivery
por: Ribeiro, Lígia N. M., et al.
Publicado: (2020)

Parenteral vs. oral sumatriptan and naratriptan: plasma levels and efficacy in migraine. A comment
por: Tfelt-Hansen, Peer
Publicado: (2007)

Investigation of the immunoreactivities of NOS enzymes and the effect of sumatriptan in adolescent rats using an experimental model of migraine
por: Kurul, Semra Hiz, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_gl873uu4fh25215lbiroe35gdm